Hood River Capital Management LLC Has $66.54 Million Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Hood River Capital Management LLC grew its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 10.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,991,573 shares of the biotechnology company's stock after acquiring an additional 846,936 shares during the period. Hood River Capital Management LLC owned 2.95% of Iovance Biotherapeutics worth $66,538,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. AlphaQuest LLC raised its stake in Iovance Biotherapeutics by 63.6% in the fourth quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 1,794 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter worth approximately $36,000. Integrity Wealth Advisors Inc. acquired a new stake in shares of Iovance Biotherapeutics during the 4th quarter worth approximately $77,000. Jump Financial LLC acquired a new position in Iovance Biotherapeutics during the fourth quarter valued at approximately $79,000. Finally, Impact Partnership Wealth LLC bought a new stake in Iovance Biotherapeutics during the fourth quarter worth $83,000. Institutional investors own 77.03% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IOVA. Truist Financial lowered their price target on Iovance Biotherapeutics from $25.00 to $15.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Piper Sandler dropped their target price on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a "neutral" rating for the company in a report on Friday, February 28th. Chardan Capital decreased their price target on shares of Iovance Biotherapeutics from $34.00 to $30.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. The Goldman Sachs Group dropped their price objective on shares of Iovance Biotherapeutics from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Iovance Biotherapeutics presently has an average rating of "Moderate Buy" and an average target price of $18.22.

Iovance Biotherapeutics Stock Performance

Shares of IOVA stock traded up $0.04 on Monday, hitting $3.55. The company had a trading volume of 3,915,790 shares, compared to its average volume of 7,586,331. Iovance Biotherapeutics, Inc. has a twelve month low of $2.70 and a twelve month high of $14.23. The firm has a market cap of $1.16 billion, a P/E ratio of -2.38 and a beta of 1.05. The stock's 50-day moving average is $3.73 and its two-hundred day moving average is $6.53.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.26). Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. The firm had revenue of $73.69 million during the quarter, compared to analyst estimates of $72.17 million. Equities research analysts predict that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.